Results 151 to 160 of about 486,907 (280)

Low‐Dose Nivolumab in Various Cancers: A Real‐World Exploratory Analysis in Resource‐Constrained Settings

Cancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Immune checkpoint inhibitors (ICIs), including nivolumab, have significantly improved cancer care. However, due to high costs, there is a significant financial barrier to their widespread access. Emerging evidence shows biological plausibility as well as efficacy of low‐dose nivolumab across different cancers.
Subhas Pandit, Simit Sapkota, Abish Adhikari, Jeebana Bhandari, Sunil Shrestha, Rajani Jha, Gerim Prasai, Anjani Kr. Jha   +7 more
wiley   +1 more source

Live‐cell FRET imaging‐based efficacy prediction of EGFR‐TKIs in EGFR L858R‐mutant NSCLC

Clinical and Translational Medicine, Volume 16, Issue 10, October 2026.
At the single‐cell level, live‐cell FRET microscopy was used to integrate the EGFRL858R‐GRB2 interaction with cellular phenotypic features to predict the efficacy of EGFR‐TKIs. The EGFRL858R‐GRB2 interaction‐based T‐score can evaluate the on‐target activity of EGFR‐TKIs against EGFRL858R.
Xin Li, Lingao Dai, Pingshan Yang, Shuanghe Li, Chuan Peng, Shiyao Li, Beini Sun, Songwang Cai, Xiaoping Wang, Tongsheng Chen   +9 more
wiley   +1 more source

Cytological Features of Clear Cell Sarcoma in Exfoliative and Effusion Cytology Specimen—A Case Report and Literature Review

Diagnostic Cytopathology, Volume 54, Issue 10, Page 731-737, October 2026.
ABSTRACT Clear cell sarcoma of soft tissue (CCSST) with malignant effusion is a rare yet clinically aggressive appearance, which may pose a diagnostic pitfall with its overlapping cytomorphologic features with metastatic melanoma and carcinoma.
William H. Wu, Joanna K. M. Ng, Joshua J. X. Li   +2 more
wiley   +1 more source

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree, Amy A. Kirkwood, Nadine Farah, Emma Lawrie, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Bela Patel, Pip Patrick, Paul Smith, Krisztina Z. Alapi, Lingyi Wang, Marc R. Mansour, Adele K. Fielding   +14 more
wiley   +1 more source

Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract Follicular lymphoma (FL) is the second most common lymphoma subtype in Europe, with a median age at diagnosis of 60–65 years. It is generally considered an indolent disease, and the median overall survival at diagnosis now likely exceeds 20 years. However, considerable heterogeneity exists.
Marco Ladetto, Natacha Bolaños, Guy Bouguet, Klaus Herfarth, Wolfram Klapper, Sirpa Leppa, Kim Linton, Armando Lopez‐Guillermo, Stefano Luminari, Franck Morschhauser, Jessica Okosun, Ewa Paszkiewicz‐Kozik, Catherine Thieblemont, Sanne Helene Tonino, Marek Trneny, Judith Trotman, Umut Yilmaz, Martin Dreyling   +17 more
wiley   +1 more source

Diagnostic Tools Used for Tuberculous Pleural Effusion and Their Association With Treatment Outcomes. [PDF]

Cureus
Mohammed A, Awouda EA, Elbadri A, Abuelgasim A.   +3 more
europepmc   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, Volume 159, Issue 7, Page 1735-1749, 1 October 2026.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Massive pleural effusion due to transdiaphragmatic extension of intrahepatic cholangiocarcinoma. [PDF]

BMJ Case Rep
Ogata T, Kamitsuma C, Kirimura S, Yamashita T.   +3 more
europepmc   +1 more source

Human biomarker navigator

iMeta, Volume 5, Issue 5, October 2026.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Low Skeletal Muscle Index Predicts Neoadjuvant Immunochemotherapy Tolerance and Survival in Oesophageal Squamous Cell Carcinoma

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 5, October 2026.
ABSTRACT Background Low skeletal muscle index (SMI) may identify host vulnerability in patients receiving intensive cancer therapy. However, its association with treatment tolerance and outcomes during neoadjuvant immunochemotherapy (nICT) for oesophageal squamous cell carcinoma (OSCC) remains unclear.
Yizhou Huang, Maohui Chen, Zhenyuan Yang, Bingqiang Cai, Yongcong Zhang, Hongjin Wang, Shuliang Zhang, Taidui Zeng, Chun Chen, Bin Zheng   +9 more
wiley   +1 more source